PolTREG S.A. (PTG) - Total Assets
Based on the latest financial reports, PolTREG S.A. (PTG) holds total assets worth zł80.19 Million PLN (≈ $22.07 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
PolTREG S.A. - Total Assets Trend (2018–2024)
This chart illustrates how PolTREG S.A.'s total assets have evolved over time, based on quarterly financial data. Also see PolTREG S.A. market capitalisation for the company's overall valuation and market capitalisation.
PolTREG S.A. - Asset Composition Analysis
Current Asset Composition (December 2024)
PolTREG S.A.'s total assets of zł80.19 Million consist of 47.0% current assets and 53.0% non-current assets. Review how much debt does PolTREG S.A. carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 44.6% |
| Accounts Receivable | zł1.70 Million | 1.7% |
| Inventory | zł727.00K | 0.7% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł797.00K | 0.8% |
| Goodwill | zł0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how PolTREG S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See PTG stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PolTREG S.A.'s current assets represent 47.0% of total assets in 2024, a decrease from 86.5% in 2018.
- Cash Position: Cash and equivalents constituted 44.6% of total assets in 2024, down from 75.6% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 1.7% of total assets.
PolTREG S.A. Competitors by Total Assets
Key competitors of PolTREG S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Genscript Biotech Corporation
F:G51
|
Germany | €4.85 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
89bio Inc
NASDAQ:ETNB
|
USA | $603.49 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.78 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
PolTREG S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.77 | 4.04 | 5.20 |
| Quick Ratio | 2.65 | 3.98 | 5.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł18.92 Million | zł40.70 Million | zł12.59 Million |
PolTREG S.A. - Advanced Valuation Insights
This section examines the relationship between PolTREG S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.59 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | -19.4% |
| Total Assets | zł102.38 Million |
| Market Capitalization | $26.95 Million USD |
Valuation Analysis
Below Book Valuation: The market values PolTREG S.A.'s assets below their book value (0.26x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: PolTREG S.A.'s assets decreased by 19.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for PolTREG S.A. (2018–2024)
The table below shows the annual total assets of PolTREG S.A. from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | zł102.38 Million ≈ $28.18 Million |
-19.45% |
| 2023-12-31 | zł127.10 Million ≈ $34.98 Million |
+3.07% |
| 2022-12-31 | zł123.31 Million ≈ $33.94 Million |
+12.99% |
| 2021-12-31 | zł109.13 Million ≈ $30.03 Million |
+571.84% |
| 2020-12-31 | zł16.24 Million ≈ $4.47 Million |
+137.30% |
| 2019-12-31 | zł6.84 Million ≈ $1.88 Million |
-34.59% |
| 2018-12-31 | zł10.46 Million ≈ $2.88 Million |
-- |
About PolTREG S.A.
Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases. It engages in the development of therapies for the treatment of type 1 diabetes in children, as well as multiple sclerosis. The company was incorporated in 2016 and is based in Gdansk, Poland.